These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 19802983

  • 1. Activity of ceftazidime against Gram-negative bacilli from paediatric patients.
    Nelson JD, Shelton S.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():179-81. PubMed ID: 19802983
    [Abstract] [Full Text] [Related]

  • 2. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN, Barry AL, Thornsberry C, Gerlach EH, Fuchs PC, Gavan TL, Sommers HM.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [Abstract] [Full Text] [Related]

  • 3. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN.
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [Abstract] [Full Text] [Related]

  • 4. The in-vitro activity of ceftazidime against clinically important pathogens.
    Knothe H, Dette GA.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
    [Abstract] [Full Text] [Related]

  • 5. Activity of ceftazidime and newer antibiotics against Gram-negative bacilli.
    Schassan HH, Fedder J.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():79-82. PubMed ID: 19802973
    [Abstract] [Full Text] [Related]

  • 6. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
    Acuna G, Johnston J, Young LS, Martin WJ.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():83-9. PubMed ID: 19810170
    [Abstract] [Full Text] [Related]

  • 7. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A, Meyran M, Huerre M.
    Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
    [Abstract] [Full Text] [Related]

  • 8. In-vitro studies with ceftazidime.
    Giamarellou H, Avlami A, Matsakas V, Kosmidis J, Daikos GK.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():73-7. PubMed ID: 19802972
    [Abstract] [Full Text] [Related]

  • 9. The activity of ceftazidime compared with those of aztreonam, newer cephalosporins and Sch 29482 against nonfermentative gram-negative bacilli.
    Schell RF, Francisco M, Bihl JA, LeFrock JL.
    Chemotherapy; 1985 Sep; 31(3):181-90. PubMed ID: 3888543
    [Abstract] [Full Text] [Related]

  • 10. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [Abstract] [Full Text] [Related]

  • 11. Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
    Bremner DA.
    Pathology; 1987 Jul; 19(3):274-6. PubMed ID: 3124067
    [Abstract] [Full Text] [Related]

  • 12. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
    Norris SM, Guenthner SH, Wenzel RP.
    J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
    [Abstract] [Full Text] [Related]

  • 13. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL, Smith RP, Ritz W.
    Chemotherapy; 1994 Aug; 40(6):391-8. PubMed ID: 7842822
    [Abstract] [Full Text] [Related]

  • 14. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
    Flamm RK, Farrell DJ, Sader HS, Jones RN.
    J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
    [Abstract] [Full Text] [Related]

  • 15. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 16. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I, Warren C, Shannon K, King A, Hanslo D.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [Abstract] [Full Text] [Related]

  • 17. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
    Johnson CC, Livornese L, Gold MJ, Pitsakis PG, Taylor S, Levison ME.
    J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
    [Abstract] [Full Text] [Related]

  • 18. [In-vitro activity of ceftriaxone on Gram-negative bacilli with various resistance phenotypes to cephalosporins. Comparison with cefotaxime, cefmenoxime, moxalactam, ceftazidime].
    Rouhan D, Le Noc P, Le Noc D.
    Pathol Biol (Paris); 1986 May; 34(5):404-9. PubMed ID: 3534713
    [Abstract] [Full Text] [Related]

  • 19. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
    Flamm RK, Sader HS, Farrell DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro activity of cefepime and four extended-spectrum beta-lactams on 1,251 aminoglycoside-resistant gram-negative hospital strains.
    Vanhoof R, Nulens E, Nyssen HJ, Hannecart-Pokorni E.
    Chemotherapy; 1992 Nov; 38(4):225-31. PubMed ID: 1473361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.